**Name of Journal**: *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 46883

**Manuscript Type**: REVIEW

**Liver graft preservation methods during cold ischemia phase and normothermic machine perfusion**

Tchilikidi KY. Liver graft preservation methods

Konstantin Y Tchilikidi

**Konstantin Y Tchilikidi,** Department of Surgery, Altai State Medical University, Barnaul 656031, Russia

**ORCID number:** Konstantin Y Tchilikidi (0000-0002-8054-5777).

**Author contributions:** Tchilikidi KY made this manuscript entirely himself.

**Conflict-of-interest statement:** No potential conflicts of interest. No financial support.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Konstantin Y Tchilikidi, MD, Assistant Professor, Lecturer, Surgeon,** Department of Surgery, Altai State Medical University,Krasnoarneysky Avenue 131-10, Barnaul 656031, Russia. k.tchilikidi@aol.com

**Telephone:** +7-385-2627005

**Fax:** +7-385-2627005

**Received:** February 26, 2019

**Peer-review started:** February 27, 2019

**First decision:** March 19, 2019

**Revised:** March 21, 2019

**Accepted:** March 24, 2019

**Article in press:**

**Published online:**

**Abstract**

The growing demand for donor organs requires measures to expand donor pool. Those include extended criteria donors, such as elderly people, steatotic livers, donation after cardiac death, etc. Static cold storage to reduce metabolic requirements developed by Collins in late 1960s is the mainstay and the golden standard for donated organ protection. Hypothermic machine perfusion provides dynamic organ preservation at 4℃ with protracted infusion of metabolic substrates to the graft during the *ex vivo* period. It has been used instead of static cold storage or after it as short perfusion in transplant center. Normothermic machine perfusion (NMP) delivers oxygen, and nutrition at physiological temperature mimicking regular environment in order to support cellular function. This would minimize effects of ischemia/reperfusion injury. Potentially, NMP may help to estimate graft functionality before implantation into a recipient. Clinical studies demonstrated at least its non-inferiority or better outcomes *vs* static cold storage. Regular grafts donated after brain death could be safely preserved with convenient static cold storage. Except for prolonged ischemia time where hypothermic machine perfusion started in transplant center could be estimated to provide possible positive reconditioning effect. Use of hypothermic machine perfusion in regular donation instead of static cold storage or in extended criteria donors requires further investigation. Multicenter randomized clinical trial supposed to be completed in December 2021. Extended criteria donors need additional measures for graft storage and assessment until its implantation. NMP is actively evaluating promising method for this purpose. Future studies are necessary for precise estimation and confirmation to issue clinical practice recommendations.

**Key words:** Liver graft preservation; Graft preservation solutions; Static cold storage; Hypothermic machine perfusion; Normothermic machine perfusion; Ischemia-reperfusion injury; Marginal grafts; Donation after cardiac death; Extended criteria donors; Transplant complications

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: This review estimates the place of static cold storage, hypothermic and normothermic machine perfusion among liver graft preservation techniques. Regular grafts donated after brain death could be safely preserved with convenient static cold storage. Except for prolonged cold ischemia time where hypothermic machine perfusion started in transplant center could be estimated to provide possible positive reconditioning effect. Use of hypothermic machine perfusion in regular donation instead of static cold storage or in extended criteria donors requires further investigation. Normothermic machine perfusion is actively evaluating promising method for extended criteria donor grafts. Future studies are necessary.

Tchilikidi KY. Liver graft preservation methods during cold ischemia phase and normothermic machine perfusion. *World J Gastrointest Surg* 2019; In press

**INTRODUCTION**

This review composed in order to estimate the place of static cold storage, hypothermic and normothermic machine perfusion (NMP) among liver graft preservation techniques.

The potential requirement for donor livers in the world is on constant rise, despite some improvement in organ donation. For example, in the United States of America every year more than 1000 patients die and even more remove from transplant list because of inappropriate state (too sick for transplant) while waiting for donor organ[1]. In Germany more than one third among about 1500 patients in transplant list does not receive transplant yearly due to organ shortage[2].

This growing demand for donor organs requires measures to expand donor pool. Several strategies have been studied including split liver transplantation, live donor liver transplantation, and use of extended criteria donors, such as elderly people, steatotic livers, donation after cardiac death, *etc*. But it has been recognized, that grafts from extended criteria donors are extensively prone to ischemia - reperfusion injury, which in turn leads to early allograft dysfunction and biliary complications[3-7]. Besides, some authors reported significant incidence of post-reperfusion syndrome (PRS), which negatively impacts both graft and patient’s morbidity and mortality[8,9]. Clinical predictors for PRS occurrence are: firs, donor/graft related factors - donation after brain or cardiac death (DBD or DCD), donor age, donor risk index, graft steatosis, second, recipient related factors - elevated MELD (Model of End-stage Liver Disease) score, left ventricular diastolic dysfunction, third, intraoperative and storage related factors - prolonged cold ischemic time (CIT), prolonged warm ischemic time (WIT), intraoperative blood loss[10,11,12]. In DCD donation many grafts left not transplanted[13] mainly due to static cold storage insufficiency for these grafts[14]. Machine perfusion is actively been studied for marginal grafts listed above.

With organ procurement oxygenated blood flow is terminated that causes inflammation and injury, triggered by deficiency of nutrient factors and ATP (adenosine triphosphate), with lactic acid accumulation in hypoxic anaerobic metabolism. Static cold storage further exaggerates such injurious processes. Disruption of electrolyte cell membrane gradients due to sodium-potassium membrane pumps damage results in cellular edema, with free calcium influx, and subsequent activation of enzyme cascade leading to cell death. Upon restoration of circulation ATP breakdown with accumulation of xanthine oxide generates free radical. Which in turn cause lipid peroxidation with cellular destruction named ischemia-reperfusion injury[15-17]. Flushing of cold preservation solution is traditional method of donor liver preservation following organ procurement and interruption of blood supply. This static cold preservation works on diminishing cellular metabolism with temperature decrease (the coenzyme Q10 effect), which limits need for ATP[18]. Despite anaerobic metabolism diminishing depletion of ATP reserve continues at low temperatures with accumulation of metabolic waste. All listed above increase risk of primary non-function, initial poor function, and biliary complications such as ischemic cholangiopathy especially in extended criteria donors[19–21]. Increasing rate of obesity in modern population and associated steatosis are additional challenges, because such livers already pose increased risk of initial pure function[22,23]. Therefore marginal livers are more susceptible to ischemia-reperfusion injury[24,25].

**STATIC COLD STORAGE**

The mainstay and the golden standard for donated organ preservation is the induction of hypothermia to reduce metabolic requirements. As it has been stated in editorial of Eghtesad *et al*[26] Alexis Carrel made the initial steps in this area by successfully preserving an artery for several days in Locke’s solution. But his work in vascular and transplant surgery overshadowed this event. Moore *et al*[27] used ice slush in the donor for simple surface cooling. Another innovation came with Kaupp *et al*[28], who proposed the core cooling concept by flushing cold solution through an aortic cannula for abdominal organs protection. Static cold storage by Collins *et al*[29] and machine perfusion by Belzer *et al*[30] developed in late 1960s were the original options in transplantation area and still in use for graft preservation today[26].

The European Liver Transplant Registry started routinely collect data in 1983. Since that point, Collins solution was the unique compound used for static liver preservation in Europe, with 450 transplants as a maximum performed per year[31]. The peak of its use came in 1987. However, after the University of Wisconsin preservation solution introduction in 1987 the latter one got to be used in 3750 transplants per year in 2001. In 1990s alternative to University of Wisconsin solution have been developed: histidine-tryptophan-ketoglutarate solution HTK has been clinically implicated since 1991, Celsior solution CE since 1998, and Institute Georges Lopez solution (IGL-1) since 2003[31,32]. Features of Euro-Collins solution which was developed in the 1970s are: it does not contain oncotic agents, but rich in glucose, and potassium-sodium[31]. Kidney preservation with relatively less time was very suitable for it, due to renal cells impermeability to glucose. But because glucose can easily enter liver and pancreatic cells, leading to subsequent loss of the osmotic effect, and also anaerobic metabolizing of glucose, inducing intracellular acidosis limited cell preservation in these organs. Later in the University of Wisconsin solution glucose was changed to lactobionate and raffinose. These other larger sugar molecules remain in the extracellular space to preserves their beneficial effect. Jamieson and Belzer *et al*[30] developed the University of Wisconsin preservation solution in mid-1980s. They conceptualize its features: impermeant and metabolically inert molecules to maintain osmotic concentration, additional administration of oxygen radical scavengers and colloid substrate - hydroxyethyl-starch[31,33]. By all the means, organ preservation time with the University of Wisconsin solution got to be prolonged from 6 to 16 h[31,34]. During hypothermic storage impermeant substrates in this preservative solution are able to protect graft cell[1,35]. In the 1990s when liver transplantations raised in the United States the University of Wisconsin preservation solution became the gold standard for preservation of the liver and other intra-abdominal organs[1,36](Table 1).

Besides of the impermeant substances (raffinose, lactobionate) for prevention of edema, the efficacy of the University of Wisconsin preservation solution is based on addition of an ATP precursor (adenosine) and anti-oxidant components (allopurinol, reduced glutathione)[31]. On the other hand, oncotic support presented mainly by hydroxyethyl-starch brings higher viscosity and also leads to tissue saturation with the preservation solution. Consequently, this can reduce washout from the graft and therefore interferes with blood flow during reperfusion[37,38]. Plus, high concentration of potassium produces activation of voltage-dependent channels with subsequent cellular depolarization[39]. Drawbacks due to hydroxyethyl-starch became the reason for development of preservation solutions without oncotic agents such as Celsior and Histidine-tryptophane-ketoglutarate (Custodiol) and others with polyethylene-glycol to substitute hydroxyethyl-starch as oncotic agent, by instance IGL-1 and Tissue and Organ Conservation Solution (SCOT)[31].

Several alternative solutions including listed above with potential benefits have been introduced and utilized in liver transplantation for graft preservation. Histidine-tryptophane-ketoglutarate solution was originally developed in the 1970s by H.J. Brettschneider as a cardioplegia solution[33,40] and was successfully implemented in organ transplantation. Its composition is based upon a philosophy of Histidine as a potent buffer, with two substrate amino-acids: Tryptophan and Ketoglutarate. Besides different buffer system compare to University of Wisconsin solution it also contains different electrolytes with low potassium[33]. First use of Custodiol for graft protection in liver transplantation started in Europe in the late 1980s, where its efficacy and safety for liver preservation has been confirmed[41,42]. The solution was not implicated in the USA until 2002. First in the United States it has been used in cadaveric and living donor liver transplantation at the University of Pittsburgh[26,43]. Histidine-tryptophane-ketoglutarate solution with its lower viscosity and potentially better penetration to the liver microcirculation prompted the evaluation of long-term outcome in liver transplantation with particular focus on biliary problems especially in donation after cardiac death (non-heart-beating donors). In addition, low potassium content obviating the need for in situ flush prior to revascularization could be beneficial specifically in the “piggyback” venous reconstruction during live donor liver transplantation[26,44]. Some studies demonstrated lower graft survival with histidine-tryptophan-ketoglutarate solution[26,32,33]. Overall, 3-year graft survival was higher with University of Wisconsin solution, IGL-1 and Celsior (75%, 75% and 73%, respectively), versus histidine-tryptophan-ketoglutarate solution (69%) (*P* < 0.0001)[32]. Donor age more than 70 years old, cold ischemia time more than 8 h, donation after cardiac death were reported by Stewart *et al*[45] as potential risk factors for histidine-tryptophan-ketoglutarate solution that associated with reduced graft survival when compared to University of Wisconsin solution[12,45]. Despite that histidine-tryptophan-ketoglutarate solution continues to be successfully applied in liver graft preservations, especially taking into account special situations that require its buffer features, low viscosity (with more rapid cooling and better washout of blood elements) and low potassium level (therefore no need for flushing before revascularization)[26,31]. For instance, Lo *et al*[46] described Custodiol as a preservation solution in “Transplantation of the Liver” for live donor liver transplant.

Celsior with its low potassium/high sodium composition had also been developed initially for a cardiac preservation in the 1990s. Latter this solution was adopted for the protection of abdominal organ grafts as another alternative to University of Wisconsin solution[31]. Particularly in liver transplantation both Celsior and histidine-tryptophan-ketoglutarate solution have been widely used in last decade[31,47-49].

There are two main features of the Institute Georges Lopez preservation solution IGL-1: polyethylene-glycol with a molecular weight of 35 KDa (kilodalton) had been used instead of hydroxyl-ethyl-starch by and the high potassium/low sodium ratio had been reversed[31]. The beneficial effects of IGL-1 in kidney and liver transplantation have been demonstrated in both experimental[50,51,53] and clinical[52,54] studies in settings of immune response, and against microcirculation dysfunction, endoplasmic reticulum stress, apoptosis. Zaouali *et al*[55,56] have shown increased efficacy of the Institute Georges Lopez preservation solution IGL-1 compare to the University of Wisconsin solution of both non-steatotic and steatotic rat liver grafts preservation[31,55-57]. Among beneficial effects of the Institute Georges Lopez preservation solution IGL-1 authors found: prevention of mitochondrial injury, oxidative stress and, therefore, hepatic damage. Those had been mediated by nitric oxide production. Though these results need confirmation especially in clinical studies, they made the Institute Georges Lopez preservation solution IGL-1 one of the first reported in static cold storage to be advantageous for suboptimal livers[31].

SCOT is based on polyethylene-glycol of smaller size, particularly with a molecular weight of 20 KDa, and low potassium/high sodium concentrations[31]. Bradley and Bejaoui *et al*[31] showed a higher renal protection in immune response settings of SCOT. Polyethylene-glycol with a molecular weight of 20 KDa supposed to be involved in so called “immune-camouflage” process, which in part is responsible for renal protection described above[31,58]. Savier *et al*[59] in retrospective study reported SCOT with polyethylene-glycol 20 KDa at concentration of 15 g/L (SCOT 15) was able to reduce transplant cholestasis *vs* University of Wisconsin preservation solution. On the other hand polyethylene-glycol with a molecular weight of 35 KDa as oncotic agent has been shown to be more efficient compare to polyethylene-glycol with a molecular weight of 20 KDa for liver graft preservation[60]. That could limit its use in liver transplantation.

Thus, Regular grafts donated after brain death could be safely preserved with convenient static cold storage. Except for prolonged cold ischemia time and extended criteria donors who need additional measures for graft storage and possible graft reconditioning until its implantation.

**HYPOTHERMIC MACHINE PERFUSION**

Hypothermic machine perfusion provides dynamic organ preservation at 4℃ with protracted infusion of metabolic substrates to the graft during the *ex vivo* period[61]. At the above temperature cellular metabolic demands decrease but does not stop completely. So provision of necessary substrates could potentially decrease amount of harmful metabolites to reduce ischemia/reperfusion stress as an advantage over static cold storage[31]. Dutkowski *et al*[62] showed hypothermic machine perfusion to protect rodent livers against reactive oxygen species whose accumulation in ischemia causes toxic effects in hepatocytes. It happens due to reduction in glutathione depletion and release of superoxide anion[31,62]. In a rat model with diet-induced fatty liver Bessems *et al*[63] demonstrated improved hepatocellular and endothelial function after hypothermic machine perfusion, as its potential for suboptimal livers[31]. Study of Guarrera *et al*[64] compared hypothermic machine perfusion and static cold storage in human liver transplantation. Hypothermic machine perfusion demonstrated beneficial effect on graft function that diminishes biochemical markers of graft preservation injury[31,64].

Success of liver hypothermic machine perfusion requires oxygen supply, unlike kidney in which oxygenation is not always critical. Oxygenated hypothermic machine perfusion (HOPE) has been shown experimentally to improve quality of liver protection in normal and extended criteria donor livers[65]. With oxygenated hypothermic machine perfusion grafts acquire ability to maintain functional integrity of hepatocytes and to restore homeostasis[31]. In rodent model of donation after cardiac death Schlegel *et al*[66] also reported a protective effect of oxygenated hypothermic machine perfusion on biliary system. Oxygenated hypothermic machine perfusion improved immunogenic up-regulation and lowered parameters of hepatocellular injury after transplantation[31,66].

Graft dysfunction in livers from extended criteria donors is caused by ischemia-reperfusion injury that negatively affects liver regeneration after surgery including hepatic resections and transplantation[2]. In last decades for acceptable preservation allografts from extended criteria donors new strategies have been implicated[67-71]. One of them is hypothermic oxygenated machine perfusion. It has been studied in preclinical animal experiments[67,23]. In those experiments hypothermic oxygenated machine perfusion showed positive effect and demonstrated to reduce damage of cellular energy status and mitochondrial, and also the incidence of biliary complications[67]. As well as it was in clinical settings. Hypothermic oxygenated organ perfusion over the portal vein performed in the transplant center using an extra-corporal organ perfusion system with full oxygen saturation shortly before the actual implantation[67]. Dutkowski *et al*[72] published first clinical study with hypothermic oxygenated machine perfusion in a cohort of patients undergoing liver transplantation with donation after cardiac death allografts. On the other hand the only legally accepted approach for organ donation in many European countries is DBD. And In this settings impact of hypothermic oxygenated machine perfusion on early graft function and postoperative complications needs further investigation[2].

Belzer introduced machine perfusion in 1960[30]. As well he was one of the authors of the University of Wisconsin preservation solution[73,74]. So there is nothing unusual that perfusion solutions used in hypothermic machine perfusion mainly had the same composition as University of Wisconsin solution except for lactobionate which was substituted by gluconate. This solution has been named Belzer-MP solution. And it’s still most frequently used perfusion solution[31].

New hypothermic machine perfusion solution, Polysol, has been described by Bessems *et al*[75]. Besides amino acids: histidine, glutamine, tryptophan it has ascorbic acid and α-tocopherol. Their report demonstrated superior ability of Polysol in liver preservation versus Belzer-MP solution, with increased bile production and lower enzyme release[31,75]. Another alternative solution for hypothermic machine perfusion is Vasosol[64]. Despite it’s basically composed on Belzer-MP solution, additional vasodilators (prostaglandin E1 and nitroglycerin), metabolic substrates (α-ketoglutarate, *L*-arginine) and antioxidants (N-acetyl-cysteine) are promising. Authors further improved Vasosol with α-tocopherol to enhance antioxidant benefit with hypothermic machine perfusion[76].

Hypothermic oxygenated machine perfusion through single (portal vein only) or dual (portal vein and hepatic artery) approach widely discusses in literature[66,77,79,80]. Use of dual perfusion is based predominantly on the proposition of better perfusion and biliary preservation leading to reduction of biliary complications in donation after cardiac death transplantation[66,78]. However, some experimental data shows effective and sufficient perfusion of liver graft including biliary system through portal vein only approach[70]. Also favorable effect of portal vein only approach in hypothermic oxygenated machine perfusion has already been successfully demonstrated by Dutkowski *et al*[72] in clinical settings. In recent article Schlegel *et al*[81] discussed possible fields of hypothermic machine perfusion application. Extended criteria donor grafts were among those possible fields. It’s based on several previous studies with few hours liver perfusion performed in transplant center before graft implantation. Despite that there is no completed multicenter randomized trial comparing hypothermic machine perfusion and static cold storage to date.

December 21, 2018 was starting date of new randomized multicenter clinical trial comparing hypothermic oxygenated machine perfusion and static cold storage for extended criteria donor grafts. ClinicalTrials.gov Identifier: NCT03837197. Estimated Primary Completion Date is December 2019. Estimated Study Completion Date is December 2021.

In summary,Hypothermic machine perfusion started in transplant center could be estimated to provide possible positive reconditioning effect for regular grafts donated after brain death with prolonged ischemia time. Use of hypothermic machine perfusion in regular donation instead of static cold storage or in extended criteria donors requires further investigation. Multicenter randomized clinical trial supposed to be completed in December 2021.

**NORMOTHERMIC MACHINE PERFUSION**

Static cold storage currently is the main method for organ preservation. For high quality liver grafts from healthy donors it works well and brings relatively low rates of early allograft dysfunction, primary non-function, and biliary complications[82,83]. Unfortunately static cold storage frequently does not provide successful protection for marginal livers from extended criteria donors, because graft and recipient complications increase unacceptably. NMP delivers oxygen, and nutrition at physiological temperature mimicking regular environment in order to support cellular function. During organ storage continuation of aerobic metabolism would minimize effects of PRS and ischemia/reperfusion injury[84–87].

The NMP concept is based on maintaining physiological support and therefore condition of the liver graft after procurement. That should diminish the risk of organ ischemic injury, because reperfusion has already started by the device, and thereby reduces risk of PRS in recipient[88]. Through application of NMP in donation after cardiac death and other marginal grafts this preservation method can protect against ischemic cholangiopathy and other biliary complications[89-91]. As it supposed by Jayant *et al*[92], possibility to establish reliable predictive markers of post-transplant function during the NMP phase, could reveal and eliminate livers at highest risk of primary non-function and initial poor function before implanting into a recipient. That opens a way for screening among increasing number of livers based on *ex situ* function and exclusion those at higher risk, the number of liver from extended criteria donors could increase significantly. The ability to observe function of livers *ex situ* brings additional advantage in order to improve their condition. Necessary supplements may be added to perfusate solution[92,93-95]. Besides that, NMP has already demonstrated significant efficacy in lung transplantation. Also there are testing series in transplantation of kidney and whole pancreas[96,97].

Since preclinical large animal studies of NMP gave promising results in porcine and rodent models[98-101], till date there are 3 commercial normothermic perfusion devices have been used in early clinical trials. Similar principles used in all of them. Differences are in degree of portability, automation, recirculating perfusate pressure and pulsatility, substrate type and delivery, and perfusion through portal vein and hepatic artery[102,103]. The first one to be clinically implicated was the Metra device by Peter Friend and colleagues developed in a partnership between the University of Oxford and OrganOx Ltd. company. It is portable, fully automated, works at temperature 37℃, uses whole blood supplemented with plasma expander (Gelofusine), bile salts, parenteral nutrition solution, heparin, insulin, and prostacyclin through a closed perfusion, continuous, non-pulsatile portal vein, and hepatic arterial flow technique[92,104]. The second one - Organ Care System follows similar principles of NMP developed by TransMedics (Andover, MA) is also portable and fully automated device[92,105]. The third one is semi-automated, with limited portability developed by Organ Assist (Groningen, Netherlands) which has temperatures range from 8℃ to 37℃. During liver perfusion hepatic arterial and portal pressures can be modulated to adjust vascular flow[92,106]. Until now the importance of device portability is still open problem. Need to transport heavy, complex equipment, provision or on-board generation of oxygen, plus great distances by road transportation or plane pose their own unique technical as well as financial challenges that markedly escalate the technology cost. Due to that more limited intervention in some institutions is now implicated: liver graft NMP since graft’s arrival to recipient center. Though it may not fully protect against ischemic cholangiopathy and hepatocyte injury, on the other hand it shows confirmation if liver graft functions before it is implanted. Another possible advantage is some perspective with developments in the future to be more flexible in liver transplantation surgery schedule during daylight hours[92].

Animal studies with pigs (30-40 kg weight) as liver donors included Landrace[107,108] and Yorkshire[109-113]. Boehnert *et al*[114] used only male pigs. Pigs in the study of St Peter *et al*[108] were gender unspecified. The DCD model has been achieved by cardiac arrest. In turn in the majority of studies cardiac arrest has been induced with potassium chloride injection[107,108,111-113]. While Boehnert *et al*[110] got it via exsanguination.

The only study to compare static cold storage with NMP following a period of static cold storage was Boehnert *et al*[110] work. In almost all reports the warm ischemia time was 60 min. Only Banan *et al*[107] had static cold storage group after 40 min of warm ischemia and NMP following 20, 40, and 60 min of warm ischemia. Cold preservation solutions were histidine-tryptophan-ketoglutarate[107,109,111-113], University of Wisconsin[110], or Euro Collins[108]. Most studies used dual perfusion through the hepatic artery and portal vein[109,111-113,107]. St Peter *et al*[108] did single arterial flush. In one study dual or single vessel flush has not been specified[110]. Also 2 studies flushed livers *ex situ*[111,113], all others - in situ[107-109,110,112].

Duration of NMP was 6[107], 8[110], 10[109,111-113], or 24[108] h. After that, researchers simulated organ implantation. For this purpose they perfused the whole blood for either 2[107], 12[110], or 24[108,109,111-113] h. At the end of the reperfusion stage transaminase levels were investigated.

Banan *et al*[107] applied a dialysis circuit as a tool for perfusion. Perfusate was delivered: by two centrifugal pumps[107], or a roller pump and a centrifugal pump[109,111-113], or the portal vein passive perfusion and the hepatic artery perfused with centrifugal pump[110,108]. Perfusate in 3 studies was whole blood[108,109,111], in 2 studies - diluted whole blood[107,111]. One study used acellular perfusate[110]. Liu *et al*[113] compared directly different perfusate solutions: the Steen solution, washed red blood cells plus Steen solution, the whole blood, and static cold storage. The whole blood and washed red blood cells in the Steen solution helped significantly improve liver function and diminish hepatocellular injury and liver function compare to groups where Steen solution was used alone and to livers on static cold storage. Washed red blood cells in Steen solution and group perfused with the whole blood had no significant difference[113]. Nostedt *et al*[115] noted that results with acellular perfusion[110] have not been replicated. Also Liu *et al*[113] suggested the need for an oxygen carrier. Further studies are needed to determine the optimal solution for NMP[115].

Another weakness of animal studies is heterogeneity. The models of porcine liver transplant differ in longevity of observation period after revascularization (7 d to 8 h). Also in study of Fondevila *et al*[116] static cold storage followed a period of NMP and this makes it hardly comparable with other reports. NMP in study of Schön *et al*[117] has been made with no period of static cold storage, and also 4 h of static cold storage followed 60 min of warm ischemia time made all grafts primary nonfunctional. Keeping in mind that warm ischemia time was 60 min in almost all reports, it supports conclusion of Reddy *et al*[14] that periods of cold storage can impact positive effects of NMP. On the other hand, in short observation period (8 h) by Boehnert *et al*[110] static cold storage followed by NMP produced less hepatocellular injury compare to static cold storage alone group. Unfortunately grafts in this study were not assessed in longer follow up. Also in discarded human livers, NMP could improve function of affected livers even after long time cold storage[118]. Further research to address NMP’s ability to safely recover and transplant DCD grafts following periods of cold storage is needed[115]. Ravikumar *et al*[119] reviewed devices for NMP. And since portable ones are now available, they should be of use to try to eliminate cold storage for such marginal livers during the transplantation procedure. Successful recovery of marginal grafts such as donated after cardiac death by use of NMP even after periods of cold storage could significantly influence its clinical implementation. Besides that, economic impact of this method of liver graft preservation has not yet been estimated although it remains to be important for clinical use of NMP in donation after cardiac death[115]. Also gradual rewarming showed promising results for that kind of marginal grafts[106,120-122]. So it may play an important role to move forward in utilizing machine perfusion after periods of static cold storage[115].

In clinical settings, Ravikumar *et al*[104] reported 20 donor livers NMPs plus 40 static cold storages with 4 donations after cardiac death in each group. Bral *et al*[123] study included 10 (4 - donations after cardiac death) NMPs and 30 (8 - donations after cardiac death) static cold storages. In Selzner *et al*[124] publication there were also 10 (2 - donations after cardiac death) NMPs and 30 (6 - donations after cardiac death) static cold storages. Liu *et al*[125] study consisted of 10 (2 - donations after cardiac death) NMPs and 40 (8 - donations after cardiac death) static cold storages. And the largest report has been made by Nasralla *et al*[126] with 137 (34 - donations after cardiac death) NMPs and 133 (21 - donations after cardiac death) static cold storages. Also in their report 16 out of discarded 48 donor livers were undergone NMPs, the rest (32) - static cold storage. Among reasons to discard there were prominent cirrhosis in donor liver, increasing lactate level, significant steatosis, intra-operatively found malignancy, more than thirty minutes warm ischemia time, and device related errors[126]. Patient’ groups in all studies were comparable in donor age, MELD score, time of NMP and static cold storage, with 2 exceptions for Bral *et al*[123] (where NMP lasted 786 min *vs* 235 min of static cold storage) and for Nasralla *et al*[126] (714 min of NMP and 465 min of static cold storage). In all studies NMP perfusate had been blood based with packed red blood cells ABO group O. Ravikumar *et al*[104], Bral *et al*[123], and Nasralla *et al*[126] additionally primed the circuit and liver with gelatin-based plasma expander (Gelofusine™, B. Braun, Melsungen, Germany), Selzner *et al*[124] used Steen solution instead. In all trials liver function characteristics such as hepatic transaminases, INR, pH, lactate level, bile production, hepatic artery, and portal vein flow during NMP were within normal range[104,123-126]. In meta-analysis of Jayant *et al*[92] median patient age was outlined within 48.0-58.0 years (range 14-85) in NMP group and 46.0-58.5 years (range 20-86) in static cold storage group. The median MELD score reported ranged within 12-21 (range 6-40) and 14-23 (range 6-37) in these groups respectively. The reported median NMP time varied considerably, from 558 to 786 min (range 210-1631 min) while median CIT on cold storage was 235-634 min (range 64-967 min)[92]. On NMP max medium AST (Aspartate Aminotransferase) level was 417-1252 U/L (range 84-15009 U/L) between days 1 and 7 in all trials. On static cold storage AST was 839-1474 U/L (range 153-8786 U/L). Median INR (International Normalized Ratio) on day 7 in NMP group was 1.05-1.1 (range 0.88-1.6) and 1.03-1.1 (range 0.90-2.2) in static cold storage group. Also on day 7 median bilirubin levels were 25-79 μmol/L (range 8-344 μmol/L) and 30-48 μmol/L (range 9-340 μmol/L) in NMP and static cold storage groups, respectively. Median alkaline phosphatase at day 7 was 139-245 U/L (range 40-626 U/L) on NMP and 147-243 U/L (range 58-743 U/L) at static cold storage[92,104,123-126](Table 2).

Only Nasralla *et al*[126] reported single primary non-function case in their randomized study in NMP group. Among studies listed above early allograft dysfunction in NMP groups ranged from 10% to 56% and from 23% to 30% in static cold storage groups. As well, Nasralla *et al*[126] in donation after cardiac death reported 93% less likelihood of early allograft dysfunction on NMP compare to static cold storage[92,126]. Also this randomized trial confirmed earlier data of Bral *et al*[123] that post reperfusion syndrome occurred less frequently in NMP group than in static cold storage group (15 cases *vs* 32)[92,125,126].

The median intensive care unit stay in reports listed above was 3-4 d (range 0-41 d) for recipients with livers after static cold storage, and for those with livers on NMP – 3-16 d (range 1-65 d)[92,104,123,124,126]. The median hospital stay for patients with grafts after static cold storage was 13-25 d (range 7-89 d) and 12-45 d (range 6-114 d) for patients with grafts with NMP[92,104,123,124,126]. Major complications (Clavien-Dindo score ≥ 3) occurred in 22%-37% and 10%-22% of recipients in static cold storage and NMP groups, respectively[92,104,123,124,126]. At 6 mo after liver transplantation biliary complications have been developed in grafts after NMP in study of Ravikumar *et al*[104] in 20% (4 patients), in study of Nasralla *et al*[126] - 10.1% (13 patients). Selzner *et al*[124] and Bral *et al*[123] did not report biliary complications at that point. Besides, Bral *et al*[123] evidenced 14.8% of biliary strictures after static cold storage compare to 0 after NMP and Nasralla *et al*[126] in recently published randomized study did not observe any statistical difference between groups for non-anastomotic biliary strictures[92,123,126].

Graft survival at 30 d, 3 mo and 6 mo was statistically insignificant between groups 80%-100% in NMP group and 97.5%-100% in static cold storage group[92,104,123,124,126]. As well as that was for 30 d mortality. It ranged 2.5%-11% after NMP and 0-2.5% after static cold storage[92,104,123,124].

By the literature, up to one-third of marginal livers are taken in donation after cardiac death despite additional risks[92,107,126–129]. In porcine models experimental data demonstrate that NMP application possibly decrease the additional risks of organs donated after cardiac death, but that is almost not proved by clinical practice[107,128]. By Brockmann *et al*[129], porcine donated after cardiac death liver grafts shows better survival and superior function versus static cold storage. In study of Fondevila *et al*[116] porcine livers donated after cardiac death with warm ischemia time up to 120 min after NMP survived 100%, and after static cold storage they had 100% mortality[92,116].

Potentially, NMP may help to estimate graft functionality before implantation into a recipient, thus decrease such risks. Currently, assessment of donor liver before implantation could only roughly predict graft survival and function. So, marginal donor livers could potentially be disastrous for recipients, with elevated risk of early allograft dysfunction, primary non-function, or other detrimental complications of ischemia-reperfusion injury, with acute renal injury after PRS[63,92,130-132].

Since NMP has been tested widely, some authors suggested that a combination of metabolic, hemodynamic, and synthetic parameters picked up during the perfusion phase can help to predict viability of the graft by providing its functional assessment[92,99,133]. And static cold storage cannot provide such a possibility. The parameters include stability of portal vein and hepatic artery flow and pressure, bile production, some metabolic parameters including ALT (Alanine Aminotransferase), AST, *etc*.[92,104,123,124,126]. Most important predictors of adequate post-transplant liver function are pH stability and repeated bicarbonate corrections, lactate clearance during NMP[92,98,99,134].

The subsequent clinical trials published by Ravikumar, Selzner, Bral, and Nasralla *et al*[104,123,124,126] used 20%, 20%, 40%, and 24.8% livers donated after cardiac death, respectively, and demonstrated similar outcomes to static cold storage controls in donated after cardiac death grafts. Recent study by Nasralla *et al*[126] (2018) outlined better outcomes with donated after cardiac death livers preserved with NMP in comparison to static cold storage group; however further studies are required to strengthen this outcome owing to limitations of inadequately powered subgroup analysis.

Bral *et al*[123] did not show significant improvement in opening transaminase levels in the recipients, likely due to their increased proportion of donations after cardiac death and prolonged cold ischemia time while a relatively higher proportion of replaced and accessory hepatic arteries were reconstructed on the back table, and their NMP duration was extended to outer limits often while their small surgical team rested overnight or were engaged in other HPB surgeries[123].

Ischemic injurious impact after static cold storage on hepatocytes and biliary epithelium was well described, despite this method of graft preservation is standard and convenient[92,110,135]. So, prolonged cold storage of marginal liver grafts may bring inacceptable risk for recipient[136-141]. Among those, primary non-function takes place in up to 5%-8%[142,143]. Association between donor risk factors and primary non-function supports its multifactorial nature[137,138], and may also be caused by technical error with inadequate blood flow[136]. If emergency re-transplantation is not possible, primary non-function leads to recipient’s death. None of the early phase NMP trials have been associated with primary non-function. Only Nasralla *et al*[126] reported single primary non-function case in their randomized study in NMP group[92,126,144].

Elevated transaminase levels within first postoperative week most likely indicate early allograft dysfunction, which brings increased risk for the patient[145-147]. In the presented studies early allograft dysfunction has been developed in 10%-55.5% after NMP. Bral *et al*[123] described 4 such events mainly occurred in livers donated after cardiac death[104,123-125]. All those grafts finally started to work properly with transaminase levels returned back to normal. Besides, in their recent randomized trial Nasralla *et al*[126] in donation after cardiac death reported 93% less likelihood of early allograft dysfunction on NMP compare to static cold storage[92,126,144].

Ischemic cholangiopathy and anastomotic biliary strictures are among the most serious complications in donation after cardiac death liver transplantation. Biliary strictures in liver transplant surgery ranges within 4%-15% for grafts donated after brain death and 30%-40% for those donated after cardiac death[22,92,140]. Pathogenesis of this potentially devastating complication includes peribiliary glands’ injury due to peribiliary vascular plexus micro-thrombi formation at the time of ischemia-reperfusion or a circulatory phase of donation after cardiac death. Later, some reports showed that thrombolytic agent, tissue plasminogen activator infused into hepatic artery dissolved and/or prevented thrombi formation in microcirculations and therefore biliary strictures[92,141,148,149]. In porcine models op den Dries *et al*[99] and Boehnert *et al*[110] study demonstrated significantly lower rate of complications related to bile duct after NMP. Liu *et al*[111] reported that differentiation of multipotent stem cells in peribiliary glands into cholangiocytes following NMP in porcine model promotes biliary epithelium regeneration that could prevent formation of biliary strictures[111,150]. Results of clinical trials were varying. At 6 mo after liver transplantation biliary complications have been developed in grafts after NMP in study of Ravikumar *et al*[104] in 20% (4 patients), in study of Nasralla *et al*[126] - 10.1% (13 patients). Selzner *et al*[124] and Bral *et al*[123] did not report biliary complications at that point. Besides, Bral *et al*[123] evidenced 14.8% of biliary strictures after static cold storage compare to 0 after NMP and Nasralla *et al*[126] in recently published randomized study did not observe any statistical difference between groups for non-anastomotic biliary strictures[92].

Extended criteria donors also include those with steatotic livers. They usually are not used as grafts, because of possibility of primary non-function development[92,134,147]. In Spitzer *et al*[151] study livers with more than 30% of macrosteatosis constituted increased risk of 71% for one-year graft loss versus those with steatosis of less than 15%. Though other reports for macrosteatosis more than 30% demonstrated successful outcomes for donors with age less than 40 year old, cold ischemia time less than 11 h, and not for donation after cardiac death[92,152,153]. In animal studies with NMP Jamieson *et al*[95] showed substantial decrease of steatosis grade in rat livers. Banan *et al*[134] and Vogel *et al*[118] reported improvement in steatosis after NMP and with additional defatting substances. Nagrath *et al*[154] got reduction in hepatic triglycerides by 65% when used so called “defatting cocktail” for steatotic rat livers to promote oxidation and to esterify hepatic triglycerides. Boteon *et al*[155] reported their regimen for defatting of primary human hepatocytes which is non-toxic to hepatocytes. cholangiocytes and intrahepatic endothelial cells. But all this studies need clinical confirmation.

Also in a recent publication Scheuermann *et al*[156] considered that inflammatory molecules accumulated during machine perfusion (so called damage‐associated molecular patterns and inflammatory cytokines) can negatively impact liver graft. The accumulation occurs in time dependent manner with noted decrease after a peak. So therapies and optimal time to attenuate them could be beneficial in further improvement of this technology[156].

Dondossolaa *et al*[157] used NMP to assess marginal liver graft function after hypothermic oxygenated machine perfusion.

To date no clinical recommendations for NMP has been issued even after multicenter randomized trial[126].

Therefore,NMP is actively evaluating promising method for extended criteria donor livers preservation. Potentially, NMP may help to estimate graft functionality before implantation into a recipient. Clinical studies demonstrated at least non-inferiority with NMP *vs* convenient static cold storage in settings of posttransplant complications, early allograft dysfunction, and primary non-function. At the current level of development possible reconditioning effect of NMP on steatotic livers has not been confirmed in clinics. Future trials are required.

**CONCLUSION**

Regular grafts donated after brain death could be safely preserved with convenient static cold storage. Except for prolonged ischemia time where hypothermic machine perfusion started in transplant center could be estimated to provide possible positive reconditioning effect. Use of hypothermic machine perfusion in regular donation instead of static cold storage or in extended criteria donors requires further investigation. Multicenter randomized clinical trial supposed to be completed in December 2021.

Extended criteria donors need additional measures for graft storage and assessment until its implantation. NMP is actively evaluating promising method for this purpose.

Future studies are necessary for precise estimation and confirmation to issue clinical practice recommendations.

**REFERENCES**

1 **Kim WR**, Lake JR, Smith JM, Schladt DP, Skeans MA, Harper AM, Wainright JL, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2016 Annual Data Report: Liver. *Am J Transplant* 2018; **18 Suppl 1**: 172-253 [PMID: 29292603 DOI: 10.1111/ajt.14559]

2 **Tacke F**, Kroy DC, Barreiros AP, Neumann UP. Liver transplantation in Germany. *Liver Transpl* 2016; **22**: 1136-1142 [PMID: 27082951 DOI: 10.1002/lt.24461]

3 **Rayhill SC**, Wu YM, Katz DA, Voigt MD, Labrecque DR, Kirby PA, Mitros FA, Kalil RS, Miller RA, Stolpen AH, Schmidt WN. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. *Transplantation* 2007; **84**: 331-339 [PMID: 17700157 DOI: 10.1097/01.tp.0000270313.31328.63]

4 **Mueller AR**, Platz KP, Kremer B. Early postoperative complications following liver transplantation. *Best Pract Res Clin Gastroenterol* 2004; **18**: 881-900 [PMID: 15494284 DOI: 10.1016/j.bpg.2004.07.004]

5 **Busuttil RW**, Tanaka K. The utility of marginal donors in liver transplantation. *Liver Transpl* 2003; **9**: 651-663 [PMID: 12827549 DOI: 10.1053/jlts.2003.50105]

6 **Foley DP**, Fernandez LA, Leverson G, Anderson M, Mezrich J, Sollinger HW, D'Alessandro A. Biliary complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long-term outcomes from a single center. *Ann Surg* 2011; **253**: 817-825 [PMID: 21475025 DOI: 10.1097/SLA.0b013e3182104784]

7 **Coffey JC**, Wanis KN, Monbaliu D, Gilbo N, Selzner M, Vachharajani N, Levstik MA, Marquez M, Doyle MBM, Pirenne J, Grant D, Heimbach JK, Chapman W, Vogt K, Hernandez-Alejandro R. The influence of functional warm ischemia time on DCD liver transplant recipients' outcomes. *Clin Transplant* 2017; **31** [PMID: 28772351 DOI: 10.1111/ctr.13068]

8 **Ayanoglu HO**, Ulukaya S, Tokat Y. Causes of postreperfusion syndrome in living or cadaveric donor liver transplantations. *Transplant Proc* 2003; **35**: 1442-1444 [PMID: 12826185]

9 **Paugam-Burtz C**, Kavafyan J, Merckx P, Dahmani S, Sommacale D, Ramsay M, Belghiti J, Mantz J. Postreperfusion syndrome during liver transplantation for cirrhosis: outcome and predictors. *Liver Transpl* 2009; **15**: 522-529 [PMID: 19399736 DOI: 10.1002/lt.21730]

10 **Xu ZD**, Xu HT, Yuan HB, Zhang H, Ji RH, Zou Z, Fu ZR, Shi XY. Postreperfusion syndrome during orthotopic liver transplantation: a single-center experience. *Hepatobiliary Pancreat Dis Int* 2012; **11**: 34-39 [PMID: 22251468 DOI: 10.1016/S1499-3872(11)60123-9]

11 **Khosravi MB**, Sattari H, Ghaffaripour S, Lahssaee M, Salahi H, Sahmeddini MA, Bahador A, Nikeghbalian S, Parsa S, Shokrizadeh S, Malek-Hosseini SA. Post-reperfusion Syndrome and Outcome Variables after Orthotopic Liver Transplantation. *Int J Organ Transplant Med* 2010; **1**: 115-120 [PMID: 25013576]

12 **de Boer MT**, Christensen MC, Asmussen M, van der Hilst CS, Hendriks HG, Slooff MJ, Porte RJ. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. *Anesth Analg* 2008; **106**: 32-44, table of contents [PMID: 18165548 DOI: 10.1213/01.ane.0000289638.26666.ed]

13 **Kim WR**, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, Harper AM, Wainright JL, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2013 Annual Data Report: liver. *Am J Transplant* 2015; **15 Suppl 2**: 1-28 [PMID: 25626341 DOI: 10.1111/ajt.13197]

14 **Reddy S**, Greenwood J, Maniakin N, Bhattacharjya S, Zilvetti M, Brockmann J, James T, Pigott D, Friend P. Non-heart-beating donor porcine livers: the adverse effect of cooling. *Liver Transpl* 2005; **11**: 35-38 [PMID: 15690534 DOI: 10.1002/lt.20287]

15 **Jaeschke H**. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. *Am J Physiol Gastrointest Liver Physiol* 2003; **284**: G15-G26 [PMID: 12488232 DOI: 10.1152/ajpgi.00342.2002]

16 **Amador A**, Grande L, Martí J, Deulofeu R, Miquel R, Solá A, Rodriguez-Laiz G, Ferrer J, Fondevila C, Charco R, Fuster J, Hotter G, García-Valdecasas JC. Ischemic pre-conditioning in deceased donor liver transplantation: a prospective randomized clinical trial. *Am J Transplant* 2007; **7**: 2180-2189 [PMID: 17697262 DOI: 10.1111/j.1600-6143.2007.01914.x]

17 **Jassem W**, Fuggle S, Thompson R, Arno M, Taylor J, Byrne J, Heaton N, Rela M. Effect of ischemic preconditioning on the genomic response to reperfusion injury in deceased donor liver transplantation. *Liver Transpl* 2009; **15**: 1750-1765 [PMID: 19938126 DOI: 10.1002/lt.21936]

18 **Belzer FO**, Southard JH. Principles of solid-organ preservation by cold storage. *Transplantation* 1988; **45**: 673-676 [PMID: 3282347 DOI: 10.1097/00007890-198804000-00001]

19 **Rauen U**, de Groot H. New insights into the cellular and molecular mechanisms of cold storage injury. *J Investig Med* 2004; **52**: 299-309 [PMID: 15551652 DOI: 10.1136/jim-52-05-29]

20 **Feng XN**, Xu X, Zheng SS. Current status and perspective of liver preservation solutions. *Hepatobiliary Pancreat Dis Int* 2006; **5**: 490-494 [PMID: 17085330]

21 **Guibert EE**, Petrenko AY, Balaban CL, Somov AY, Rodriguez JV, Fuller BJ. Organ Preservation: Current Concepts and New Strategies for the Next Decade. *Transfus Med Hemother* 2011; **38**: 125-142 [PMID: 21566713 DOI: 10.1159/000327033]

22 **Op den Dries S**, Sutton ME, Lisman T, Porte RJ. Protection of bile ducts in liver transplantation: looking beyond ischemia. *Transplantation* 2011; **92**: 373-379 [PMID: 21629175 DOI: 10.1097/TP.0b013e318223a384]

23 **Op den Dries S**, Sutton ME, Karimian N, de Boer MT, Wiersema-Buist J, Gouw AS, Leuvenink HG, Lisman T, Porte RJ. Hypothermic oxygenated machine perfusion prevents arteriolonecrosis of the peribiliary plexus in pig livers donated after circulatory death. *PLoS One* 2014; **9**: e88521 [PMID: 24551114 DOI: 10.1371/journal.pone.0088521]

24 **Zhai Y**, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation--from bench to bedside. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 79-89 [PMID: 23229329 DOI: 10.1038/nrgastro.2012.225]

25 **Gracia-Sancho J,** Casillas-Ramírez A, Peralta C. Molecular pathways in protecting the liver from ischaemia/reperfusion injury: a 2015 update. *Clin Sci (Lond)* 2015; **129**: 345-362 [PMID: 26014222 DOI: 10.1042/CS20150223]

26 **Eghtesad B**, Aucejo F, Fung JJ. Preservation solutions in liver transplantation: what are the options? *Liver Transpl* 2006; **12**: 196-198 [PMID: 16447207]

27 **Moore FD**, Smith LL, Burnap TK, Dallenbach FD, Dammin GJ, Gruber UF, Shoemaker WC, Steenburg RW, Ball MR, Belko JS. One-stage homotransplantation of the liver following total hepatectomy in dogs. *Transplant Bull* 1959; **6**: 103-107 [PMID: 13635834 DOI: 10.1097/00006534-195901000-00041]

28 **Kaupp HA Jr**, Starzl TE. The use of an external bypass during experimental total hepatectomy. *Surgery* 1960; **48**: 330-331 [PMID: 14404925]

29 **Collins GM**, Bravo-Shugarman M, Terasaki PI. Kidney preservation for transportation. Initial perfusion and 30 hours' ice storage. *Lancet* 1969; **2**: 1219-1222 [PMID: 4187813 DOI: 10.1016/S0140-6736(69)90753-3]

30 **Belzer FO**, Ashby BS, Dunphy JE. 24-hour and 72-hour preservation of canine kidneys. *Lancet* 1967; **2**: 536-538 [PMID: 4166894 DOI: 10.1016/S0140-6736(67)90498-9]

31 **Bejaoui M**, Pantazi E, Folch-Puy E, Baptista PM, García-Gil A, Adam R, Roselló-Catafau J. Emerging concepts in liver graft preservation. *World J Gastroenterol* 2015; **21**: 396-407 [PMID: 25593455 DOI: 10.3748/wjg.v21.i2.396]

32 **Adam R**, Delvart V, Karam V, Ducerf C, Navarro F, Letoublon C, Belghiti J, Pezet D, Castaing D, Le Treut YP, Gugenheim J, Bachellier P, Pirenne J, Muiesan P; ELTR contributing centres, the European Liver, Intestine Transplant Association (ELITA). Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry. *Am J Transplant* 2015; **15**: 395-406 [PMID: 25612492 DOI: 10.1111/ajt.13060]

33 **Mangus RS**, Tector AJ, Agarwal A, Vianna R, Murdock P, Fridell JA. Comparison of histidine-tryptophan-ketoglutarate solution (HTK) and University of Wisconsin solution (UW) in adult liver transplantation. *Liver Transpl* 2006; **12**: 226-230 [PMID: 16447203 DOI: 10.1002/lt.20552]

34 **Southard JH**, Belzer FO. Organ preservation. *Annu Rev Med* 1995; **46**: 235-247 [PMID: 7598460 DOI: 10.1146/annurev.med.46.1.235]

35 **Jamieson NV**, Sundberg R, Lindell S, Claesson K, Moen J, Vreugdenhil PK, Wight DG, Southard JH, Belzer FO. Preservation of the canine liver for 24-48 hours using simple cold storage with UW solution. *Transplantation* 1988; **46**: 517-522 [PMID: 3051558]

36 **Todo S**, Nery J, Yanaga K, Podesta L, Gordon RD, Starzl TE. Extended preservation of human liver grafts with UW solution. *JAMA* 1989; **261**: 711-714 [PMID: 2642982 DOI: 10.1001/jama.1989.03420050061039]

37 **Morariu AM**, Vd Plaats A, V Oeveren W, 'T Hart NA, Leuvenink HG, Graaff R, Ploeg RJ, Rakhorst G. Hyperaggregating effect of hydroxyethyl starch components and University of Wisconsin solution on human red blood cells: a risk of impaired graft perfusion in organ procurement? *Transplantation* 2003; **76**: 37-43 [PMID: 12865783 DOI: 10.1097/01.TP.0000068044.84652.9F]

38 **Zaouali MA**, Ben Abdennebi H, Padrissa-Altés S, Mahfoudh-Boussaid A, Roselló-Catafau J. Pharmacological strategies against cold ischemia reperfusion injury. *Expert Opin Pharmacother* 2010; **11**: 537-555 [PMID: 20163266 DOI: 10.1517/14656560903547836]

39 **Ben Abdennebi H**, Steghens JP, Margonari J, Ramella-Virieux S, Barbieux A, Boillot O. High-Na+ low-K+ UW cold storage solution reduces reperfusion injuries of the rat liver graft. *Transpl Int* 1998; **11**: 223-230 [PMID: 9638853 DOI: 10.1111/j.1432-2277.1998.tb00806.x]

40 **Bretschneider HJ**. Myocardial protection. *Thorac Cardiovasc Surg* 1980; **28**: 295-302 [PMID: 6161427 DOI: 10.1055/s-2007-1022099]

41 **Gubernatis G**, Pichlmayr R, Lamesch P, Grosse H, Bornscheuer A, Meyer HJ, Ringe B, Farle M, Bretschneider HJ. HTK-solution (Bretschneider) for human liver transplantation. First clinical experiences. *Langenbecks Arch Chir* 1990; **375**: 66-70 [PMID: 2109816 DOI: 10.1007/BF00713388]

42 **Erhard J**, Lange R, Scherer R, Kox WJ, Bretschneider HJ, Gebhard MM, Eigler FW. Comparison of histidine-tryptophan-ketoglutarate (HTK) solution versus University of Wisconsin (UW) solution for organ preservation in human liver transplantation. A prospective, randomized study. *Transpl Int* 1994; **7**: 177-181 [PMID: 8060466 DOI: 10.1111/j.1432-2277.1994.tb01287.x]

43 **Rayya F**, Harms J, Martin AP, Bartels M, Hauss J, Fangmann J. Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution in adult liver transplantation. *Transplant Proc* 2008; **40**: 891-894 [PMID: 18555073 DOI: 10.1016/j.transproceed.2008.03.044]

44 **Chan SC**, Liu CL, Lo CM, Fan ST. Applicability of histidine-tryptophan-ketoglutarate solution in right lobe adult-to-adult live donor liver transplantation. *Liver Transpl* 2004; **10**: 1415-1421 [PMID: 15497150 DOI: 10.1002/lt.20243]

45 **Stewart ZA**, Cameron AM, Singer AL, Montgomery RA, Segev DL. Histidine-Tryptophan-Ketoglutarate (HTK) is associated with reduced graft survival in deceased donor livers, especially those donated after cardiac death. *Am J Transplant* 2009; **9**: 286-293 [PMID: 19067658 DOI: 10.1111/j.1600-6143.2008.02478.x]

46 **Lo CM,** Chan SC. Chapter 50 - Adult Living Donor Right Hepatectomy and Recipient Operation. In: Busuttil R, Klintmalm G. Transplantation of the Liver. 3rd Ed. Elsevier, Saunders 2015: 667-675 [DOI: 10.1016/B978-1-4557-0268-8.00050-6]

47 **Boudjema K**, Grandadam S, Compagnon P, Salamé E, Wolf P, Ducerf C, Le Treut P, Soubrane O, Cherqui D, Mouchel C, Renault A, Bellissant E. Efficacy and safety of Celsior preservation fluid in liver transplantation: one-year follow up of a prospective, multicenter, non-randomized study. *Clin Transplant* 2012; **26**: 199-207 [PMID: 21517997 DOI: 10.1111/j.1399-0012.2011.01447.x]

48 **OʼCallaghan JM**, Morgan RD, Knight SR, Morris PJ. The effect of preservation solutions for storage of liver allografts on transplant outcomes: a systematic review and meta-analysis. *Ann Surg* 2014; **260**: 46-55 [PMID: 24374537 DOI: 10.1097/SLA.0000000000000402]

49 **Pokorny H**, Rasoul-Rockenschaub S, Langer F, Windhager T, Rosenstingl A, Lange R, Königsrainer A, Ringe B, Mühlbacher F, Steininger R. Histidine-tryptophan-ketoglutarate solution for organ preservation in human liver transplantation-a prospective multi-centre observation study. *Transpl Int* 2004; **17**: 256-260 [PMID: 15160235 DOI: 10.1007/s00147-004-0709-4]

50 **Mosbah IB**, Zaouali MA, Martel C, Bjaoui M, Abdennebi HB, Hotter G, Brenner C, Roselló-Catafau J. IGL-1 solution reduces endoplasmic reticulum stress and apoptosis in rat liver transplantation. *Cell Death Dis* 2012; **3**: e279 [PMID: 22402603 DOI: 10.1038/cddis.2012.12]

51 **Ben Mosbah I**, Casillas-Ramírez A, Xaus C, Serafín A, Roselló-Catafau J, Peralta C. Trimetazidine: is it a promising drug for use in steatotic grafts? *World J Gastroenterol* 2006; **12**: 908-914 [PMID: 16521219 DOI: 10.3748/wjg.v12.i6.908]

52 **Codas R**, Petruzzo P, Morelon E, Lefrançois N, Danjou F, Berthillot C, Contu P, Espa M, Martin X, Badet L. IGL-1 solution in kidney transplantation: first multi-center study. *Clin Transplant* 2009; **23**: 337-342 [PMID: 19210685 DOI: 10.1111/j.1399-0012.2009.00959.x]

53 **Badet L**, Abdennebi HB, Petruzzo P, McGregor B, Espa M, Hadj-Aissa A, Ramella-Virieux S, Steghens JP, Portoghese F, Morelon E, Martin X. [Evaluation of IGL-1, a new organ preservation solution: preclinical results in renal transplantation]. *Prog Urol* 2005; **15**: 481-8; discussion 487 [PMID: 16097154]

54 **Dondéro F**, Paugam-Burtz C, Danjou F, Stocco J, Durand F, Belghiti J. A randomized study comparing IGL-1 to the University of Wisconsin preservation solution in liver transplantation. *Ann Transplant* 2010; **15**: 7-14 [PMID: 21183870]

55 **Zaouali MA**, Ben Abdennebi H, Padrissa-Altés S, Alfany-Fernandez I, Rimola A, Roselló-Catafau J. How Institut Georges Lopez preservation solution protects nonsteatotic and steatotic livers against ischemia-reperfusion injury. *Transplant Proc* 2011; **43**: 77-79 [PMID: 21335159 DOI: 10.1016/j.transproceed.2010.12.026]

56 **Zaouali MA**, Ben Mosbah I, Boncompagni E, Ben Abdennebi H, Mitjavila MT, Bartrons R, Freitas I, Rimola A, Roselló-Catafau J. Hypoxia inducible factor-1alpha accumulation in steatotic liver preservation: role of nitric oxide. *World J Gastroenterol* 2010; **16**: 3499-3509 [PMID: 20653058 DOI: 10.3748/wjg.v16.i28.3499]

57 **Ben Mosbah I**, Roselló-Catafau J, Franco-Gou R, Abdennebi HB, Saidane D, Ramella-Virieux S, Boillot O, Peralta C. Preservation of steatotic livers in IGL-1 solution. *Liver Transpl* 2006; **12**: 1215-1223 [PMID: 16724331 DOI: 10.1002/lt.20788]

58 **Bradley JA**. Effect of polyethylene glycol-based preservation solutions on graft injury in experimental kidney transplantation (Br J Surg 2010; 98: 368-378). *Br J Surg* 2011; **98**: 378-379 [PMID: 21254011 DOI: 10.1002/bjs.7389]

59 **Savier E**, Granger B, Charlotte F, Cormillot N, Siksik JM, Vaillant JC, Hannoun L. Liver preservation with SCOT 15 solution decreases posttransplantation cholestasis compared with University of Wisconsin solution: a retrospective study. *Transplant Proc* 2011; **43**: 3402-3407 [PMID: 22099807 DOI: 10.1016/j.transproceed.2011.09.054]

60 **Mosbah IB**, Saidane D, Peralta C, Roselló-Catafau J, Abdennebi HB. Efficacy of polyethylene glycols in University of Wisconsin preservation solutions: a study of isolated perfused rat liver. *Transplant Proc* 2005; **37**: 3948-3950 [PMID: 16386593 DOI: 10.1016/j.transproceed.2005.10.038]

61 **Henry SD**, Nachber E, Tulipan J, Stone J, Bae C, Reznik L, Kato T, Samstein B, Emond JC, Guarrera JV. Hypothermic machine preservation reduces molecular markers of ischemia/reperfusion injury in human liver transplantation. *Am J Transplant* 2012; **12**: 2477-2486 [PMID: 22594953 DOI: 10.1111/j.1600-6143.2012.04086.x]

62 **Dutkowski P**, Schönfeld S, Heinrich T, Watzka M, Winkelbach V, Krysiak M, Odermatt B, Junginger T. Reduced oxidative stress during acellular reperfusion of the rat liver after hypothermic oscillating perfusion. *Transplantation* 1999; **68**: 44-50 [PMID: 10428265 DOI: 10.1097/00007890-199907150-00009]

63 **Bessems M**, Doorschodt BM, Kolkert JL, Vetelainen RL, van Vliet AK, Vreeling H, van Marle J, van Gulik TM. Preservation of steatotic livers: a comparison between cold storage and machine perfusion preservation. *Liver Transpl* 2007; **13**: 497-504 [PMID: 17394146 DOI: 10.1002/lt.21039]

64 **Guarrera JV**, Henry SD, Samstein B, Odeh-Ramadan R, Kinkhabwala M, Goldstein MJ, Ratner LE, Renz JF, Lee HT, Brown RS Jr, Emond JC. Hypothermic machine preservation in human liver transplantation: the first clinical series. *Am J Transplant* 2010; **10**: 372-381 [PMID: 19958323 DOI: 10.1111/j.1600-6143.2009.02932.x]

65 **Vekemans K**, Liu Q, Brassil J, Komuta M, Pirenne J, Monbaliu D. Influence of flow and addition of oxygen during porcine liver hypothermic machine perfusion. *Transplant Proc* 2007; **39**: 2647-2651 [PMID: 17954199 DOI: 10.1016/j.transproceed.2007.08.007]

66 **Schlegel A**, Graf R, Clavien PA, Dutkowski P. Hypothermic oxygenated perfusion (HOPE) protects from biliary injury in a rodent model of DCD liver transplantation. *J Hepatol* 2013; **59**: 984-991 [PMID: 23820408 DOI: 10.1016/j.jhep.2013.06.022]

67 **Schlegel A**, Kron P, Dutkowski P. Hypothermic machine perfusion in liver transplantation. *Curr Opin Organ Transplant* 2016; **21**: 308-314 [PMID: 26918882 DOI: 10.1097/MOT.0000000000000303]

68 **Marecki H**, Bozorgzadeh A, Porte RJ, Leuvenink HG, Uygun K, Martins PN. Liver ex situ machine perfusion preservation: A review of the methodology and results of large animal studies and clinical trials. *Liver Transpl* 2017; **23**: 679-695 [PMID: 28240817 DOI: 10.1002/lt.24751]

69 **Gurusamy KS**, Gonzalez HD, Davidson BR. Current protective strategies in liver surgery. *World J Gastroenterol* 2010; **16**: 6098-6103 [PMID: 21182224 DOI: 10.3748/wjg.v16.i48.6098]

70 **Compagnon P**, Levesque E, Hentati H, Disabato M, Calderaro J, Feray C, Corlu A, Cohen JL, Ben Mosbah I, Azoulay D. An Oxygenated and Transportable Machine Perfusion System Fully Rescues Liver Grafts Exposed to Lethal Ischemic Damage in a Pig Model of DCD Liver Transplantation. *Transplantation* 2017; **101**: e205-e213 [PMID: 28403128 DOI: 10.1097/TP.0000000000001764]

71 **Ceresa CDL**, Nasralla D, Knight S, Friend PJ. Cold storage or normothermic perfusion for liver transplantation: probable application and indications. *Curr Opin Organ Transplant* 2017; **22**: 300-305 [PMID: 28301388 DOI: 10.1097/MOT.0000000000000410]

72 **Dutkowski P**, Polak WG, Muiesan P, Schlegel A, Verhoeven CJ, Scalera I, DeOliveira ML, Kron P, Clavien PA. First Comparison of Hypothermic Oxygenated PErfusion Versus Static Cold Storage of Human Donation After Cardiac Death Liver Transplants: An International-matched Case Analysis. *Ann Surg* 2015; **262**: 764-70; discussion 770-1 [PMID: 26583664 DOI: 10.1097/SLA.0000000000001473]

73 **Jamieson NV**, Lindell S, Sundberg R, Southard JH, Belzer FO. An analysis of the components in UW solution using the isolated perfused rabbit liver. *Transplantation* 1988; **46**: 512-516 [PMID: 3176157 DOI: 10.1097/00007890-198810000-00009]

74 **Jamieson NV**, Sundberg R, Lindell S, Claesson K, Moen J, Vreugdenhil PK, Wight DG, Southard JH, Belzer FO. The 24- to 48-hour preservation of canine liver by simple cold storage using UW lactobionate solution. *Transplant Proc* 1989; **21**: 1292-1293 [PMID: 2652427]

75 **Bessems M**, Doorschodt BM, van Vliet AK, van Gulik TM. Improved rat liver preservation by hypothermic continuous machine perfusion using polysol, a new, enriched preservation solution. *Liver Transpl* 2005; **11**: 539-546 [PMID: 15838888 DOI: 10.1002/lt.20388]

76 **Bae C**, Pichardo EM, Huang H, Henry SD, Guarrera JV. The benefits of hypothermic machine perfusion are enhanced with Vasosol and α-tocopherol in rodent donation after cardiac death livers. *Transplant Proc* 2014; **46**: 1560-1566 [PMID: 24880463 DOI: 10.1016/j.transproceed.2013.12.050]

77 **Schlegel A**, Dutkowski P. Role of hypothermic machine perfusion in liver transplantation. *Transpl Int* 2015; **28**: 677-689 [PMID: 24852621 DOI: 10.1111/tri.12354]

78 **van Rijn R**, Karimian N, Matton APM, Burlage LC, Westerkamp AC, van den Berg AP, de Kleine RHJ, de Boer MT, Lisman T, Porte RJ. Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death. *Br J Surg* 2017; **104**: 907-917 [PMID: 28394402 DOI: 10.1002/bjs.10515]

79 **Schlegel A**, Kron P, De Oliveira ML, Clavien PA, Dutkowski P. Is single portal vein approach sufficient for hypothermic machine perfusion of DCD liver grafts? *J Hepatol* 2016; **64**: 239-241 [PMID: 26432684 DOI: 10.1016/j.jhep.2015.09.015]

80 **Brüggenwirth IMA**, Burlage LC, Porte RJ, Martins PN. Is single portal vein perfusion the best approach for machine preservation of liver grafts? *J Hepatol* 2016; **64**: 1194-1195 [PMID: 26836281 DOI: 10.1016/j.jhep.2015.12.025]

81 **Schlegel A**, Muller X, Dutkowski P. Hypothermic Machine Preservation of the Liver: State of the Art. *Curr Transplant Rep* 2018; **5**: 93-102 [PMID: 29564206 DOI: 10.1007/s40472-018-0183-z]

82 **Sanchez-Urdazpal L**, Gores GJ, Ward EM, Maus TP, Wahlstrom HE, Moore SB, Wiesner RH, Krom RA. Ischemic-type biliary complications after orthotopic liver transplantation. *Hepatology* 1992; **16**: 49-53 [PMID: 1618482 DOI: 10.1002/hep.1840160110]

83 **Carini R**, De Cesaris MG, Bellomo G, Albano E. Intracellular Na+ accumulation and hepatocyte injury during cold storage. *Transplantation* 1999; **68**: 294-297 [PMID: 10440404 DOI: 10.1097/00007890-199907270-00023]

84 **Xu H**, Berendsen T, Kim K, Soto-Gutiérrez A, Bertheium F, Yarmush ML, Hertl M. Excorporeal normothermic machine perfusion resuscitates pig DCD livers with extended warm ischemia. *J Surg Res* 2012; **173**: e83-e88 [PMID: 22099594 DOI: 10.1016/j.jss.2011.09.057]

85 **Tolboom H**, Milwid JM, Izamis ML, Uygun K, Berthiaume F, Yarmush ML. Sequential cold storage and normothermic perfusion of the ischemic rat liver. *Transplant Proc* 2008; **40**: 1306-1309 [PMID: 18589093 DOI: 10.1016/j.transproceed.2008.03.100]

86 **Tillou X**, Thuret R, Doerfler A; CTAFU. Ischemia/reperfusion during normothermic perfusion. *Prog Urol* 2014; **24 Suppl 1**: S51-S55 [PMID: 24950934 DOI: 10.1016/S1166-7087(14)70064-8]

87 **Angelico R**, Perera MT, Ravikumar R, Holroyd D, Coussios C, Mergental H, Isaac JR, Iqbal A, Cilliers H, Muiesan P, Friend PJ, Mirza DF. Normothermic Machine Perfusion of Deceased Donor Liver Grafts Is Associated With Improved Postreperfusion Hemodynamics. *Transplant Direct* 2016; **2**: e97 [PMID: 27795989 DOI: 10.1097/TXD.0000000000000611]

88 **Schlegel A**, de Rougemont O, Graf R, Clavien PA, Dutkowski P. Protective mechanisms of end-ischemic cold machine perfusion in DCD liver grafts. *J Hepatol* 2013; **58**: 278-286 [PMID: 23063573 DOI: 10.1016/j.jhep.2012.10.004]

89 **Op den Dries S**, Karimian N, Westerkamp AC, Sutton ME, Kuipers M, Wiersema-Buist J, Ottens PJ, Kuipers J, Giepmans BN, Leuvenink HG, Lisman T, Porte RJ. Normothermic machine perfusion reduces bile duct injury and improves biliary epithelial function in rat donor livers. *Liver Transpl* 2016; **22**: 994-1005 [PMID: 26946466 DOI: 10.1002/lt.24436]

90 **Warnecke G**, Moradiellos J, Tudorache I, Kühn C, Avsar M, Wiegmann B, Sommer W, Ius F, Kunze C, Gottlieb J, Varela A, Haverich A. Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients. *Lancet* 2012; **380**: 1851-1858 [PMID: 23063317 DOI: 10.1016/S0140-6736(12)61344-0]

91 **Cypel M**, Rubacha M, Yeung J, Hirayama S, Torbicki K, Madonik M, Fischer S, Hwang D, Pierre A, Waddell TK, de Perrot M, Liu M, Keshavjee S. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. *Am J Transplant* 2009; **9**: 2262-2269 [PMID: 19663886 DOI: 10.1111/j.1600-6143.2009.02775.x]

92 **Jayant K**, Reccia I, Virdis F, Shapiro AMJ. The Role of Normothermic Perfusion in Liver Transplantation (TRaNsIT Study): A Systematic Review of Preliminary Studies. *HPB Surg* 2018; **2018**: 6360423 [PMID: 29887782 DOI: 10.1155/2018/6360423]

93 **Baskin-Bey ES**, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, Burgart L, Garrity-Park M, van Vilsteren FG, Oliver LK, Rosen CB, Gores GJ. Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. *Am J Transplant* 2007; **7**: 218-225 [PMID: 17227570 DOI: 10.1111/j.1600-6143.2006.01595.x]

94 **Busuttil RW**, Lipshutz GS, Kupiec-Weglinski JW, Ponthieux S, Gjertson DW, Cheadle C, Watkins T, Ehrlich E, Katz E, Squiers EC, Rabb H, Hemmerich S. rPSGL-Ig for improvement of early liver allograft function: a double-blind, placebo-controlled, single-center phase II study. *Am J Transplant* 2011; **11**: 786-797 [PMID: 21401865 DOI: 10.1111/j.1600-6143.2011.03441.x]

95 **Jamieson RW**, Zilvetti M, Roy D, Hughes D, Morovat A, Coussios CC, Friend PJ. Hepatic steatosis and normothermic perfusion-preliminary experiments in a porcine model. *Transplantation* 2011; **92**: 289-295 [PMID: 21681143 DOI: 10.1097/TP.0b013e318223d817]

96 **Hamaoui K**, Gowers S, Sandhu B, Vallant N, Cook T, Boutelle M, Casanova D, Papalois V. Development of pancreatic machine perfusion: translational steps from porcine to human models. *J Surg Res* 2018; **223**: 263-274 [PMID: 29325720 DOI: 10.1016/j.jss.2017.11.052]

97 **Nicholson ML**, Hosgood SA. Renal transplantation after ex vivo normothermic perfusion: the first clinical study. *Am J Transplant* 2013; **13**: 1246-1252 [PMID: 23433047 DOI: 10.1111/ajt.12179]

98 **Sutton ME**, op den Dries S, Karimian N, Weeder PD, de Boer MT, Wiersema-Buist J, Gouw AS, Leuvenink HG, Lisman T, Porte RJ. Criteria for viability assessment of discarded human donor livers during ex vivo normothermic machine perfusion. *PLoS One* 2014; **9**: e110642 [PMID: 25369327 DOI: 10.1371/journal.pone.0110642]

99 **op den Dries S**, Karimian N, Sutton ME, Westerkamp AC, Nijsten MW, Gouw AS, Wiersema-Buist J, Lisman T, Leuvenink HG, Porte RJ. Ex vivo normothermic machine perfusion and viability testing of discarded human donor livers. *Am J Transplant* 2013; **13**: 1327-1335 [PMID: 23463950 DOI: 10.1111/ajt.12187]

100 **Yska MJ**, Buis CI, Monbaliu D, Schuurs TA, Gouw AS, Kahmann ON, Visser DS, Pirenne J, Porte RJ. The role of bile salt toxicity in the pathogenesis of bile duct injury after non-heart-beating porcine liver transplantation. *Transplantation* 2008; **85**: 1625-1631 [PMID: 18551070 DOI: 10.1097/TP.0b013e318170f5f7]

101 **Graham JA**, Guarrera JV. "Resuscitation" of marginal liver allografts for transplantation with machine perfusion technology. *J Hepatol* 2014; **61**: 418-431 [PMID: 24768755 DOI: 10.1016/j.jhep.2014.04.019]

102 **Laing RW**, Mergental H, Mirza DF. Normothermic ex-situ liver preservation: the new gold standard. *Curr Opin Organ Transplant* 2017; **22**: 274-280 [PMID: 28333889 DOI: 10.1097/MOT.0000000000000414]

103 **Vogel T**, Brockmann JG, Friend PJ. Ex-vivo normothermic liver perfusion: an update. *Curr Opin Organ Transplant* 2010; **15**: 167-172 [PMID: 20186059 DOI: 10.1097/MOT.0b013e328337349d]

104 **Ravikumar R,** Jassem W, Mergental H, Heaton N, Mirza D, Perera MT, Quaglia A, Holroyd D, Vogel T, Coussios CC, Friend PJ. Liver Transplantation After Ex Vivo Normothermic Machine Preservation: A Phase 1 (First-in-Man) Clinical Trial. *Am J Transplant* 2016; **16**: 1779-**1787** [PMID: 26752191 DOI: 10.1111/ajt.13708]

105 2017 American Transplant Congress Abstracts. *Am J Transplant* 2017; **17 Suppl 3**: 5-815 [PMID: 28423219 DOI: 10.1111/ajt.14304]

106 **Minor T**, Efferz P, Fox M, Wohlschlaeger J, Lüer B. Controlled oxygenated rewarming of cold stored liver grafts by thermally graduated machine perfusion prior to reperfusion. *Am J Transplant* 2013; **13**: 1450-1460 [PMID: 23617781 DOI: 10.1111/ajt.12235]

107 **Banan B**, Chung H, Xiao Z, Tarabishy Y, Jia J, Manning P, Upadhya GA, Mohanakumar T, Lin Y, Chapman WC. Normothermic extracorporeal liver perfusion for donation after cardiac death (DCD) livers. *Surgery* 2015; **158**: 1642-1650 [PMID: 26294088 DOI: 10.1016/j.surg.2015.07.016]

108 **St Peter SD**, Imber CJ, Lopez I, Hughes D, Friend PJ. Extended preservation of non-heart-beating donor livers with normothermic machine perfusion. *Br J Surg* 2002; **89**: 609-616 [PMID: 11972552 DOI: 10.1046/j.1365-2168.2002.02052.x]

109 **Nassar A**, Liu Q, Farias K, Buccini L, Baldwin W, Bennett A, Mangino M, Irefin S, Cywinski J, Okamoto T, Diago Uso T, Iuppa G, Soliman B, Miller C, Quintini C. Impact of Temperature on Porcine Liver Machine Perfusion From Donors After Cardiac Death. *Artif Organs* 2016; **40**: 999-1008 [PMID: 27086771 DOI: 10.1111/aor.12699]

110 **Boehnert MU**, Yeung JC, Bazerbachi F, Knaak JM, Selzner N, McGilvray ID, Rotstein OD, Adeyi OA, Kandel SM, Rogalla P, Yip PM, Levy GA, Keshavjee S, Grant DR, Selzner M. Normothermic acellular ex vivo liver perfusion reduces liver and bile duct injury of pig livers retrieved after cardiac death. *Am J Transplant* 2013; **13**: 1441-1449 [PMID: 23668775 DOI: 10.1111/ajt.12224]

111 **Liu Q**, Nassar A, Farias K, Buccini L, Baldwin W, Mangino M, Bennett A, O'Rourke C, Okamoto T, Uso TD, Fung J, Abu-Elmagd K, Miller C, Quintini C. Sanguineous normothermic machine perfusion improves hemodynamics and biliary epithelial regeneration in donation after cardiac death porcine livers. *Liver Transpl* 2014; **20**: 987-999 [PMID: 24805852 DOI: 10.1002/lt.23906]

112 **Nassar A**, Liu Q, Farias K, D'Amico G, Tom C, Grady P, Bennett A, Diago Uso T, Eghtesad B, Kelly D, Fung J, Abu-Elmagd K, Miller C, Quintini C. Ex vivo normothermic machine perfusion is safe, simple, and reliable: results from a large animal model. *Surg Innov* 2015; **22**: 61-69 [PMID: 24694840 DOI: 10.1177/1553350614528383]

113 **Liu Q**, Nassar A, Farias K, Buccini L, Mangino MJ, Baldwin W, Bennett A, O'Rourke C, Iuppa G, Soliman BG, Urcuyo-Llanes D, Okamoto T, Uso TD, Fung J, Abu-Elmagd K, Miller C, Quintini C. Comparing Normothermic Machine Perfusion Preservation With Different Perfusates on Porcine Livers From Donors After Circulatory Death. *Am J Transplant* 2016; **16**: 794-807 [PMID: 26663737 DOI: 10.1111/ajt.13546]

114 **Boehnert MU**, Yeung JC, Knaak JM, Selzner N, Selzner M. Normothermic acellular ex vivo liver perfusion (NEVLP) reduces liver and bile duct in DCD liver grafts. *Am J Transplant* 2013; **13**: 3290 [PMID: 24165042 DOI: 10.1111/ajt.12495]

115 **Nostedt JJ**, Skubleny DT, Shapiro AMJ, Campbell S, Freed DH, Bigam DL. Normothermic Ex Vivo Machine Perfusion for Liver Grafts Recovered from Donors after Circulatory Death: A Systematic Review and Meta-Analysis. *HPB Surg* 2018; **2018**: 6867986 [PMID: 29849531 DOI: 10.1155/2018/6867986]

116 **Fondevila C**, Hessheimer AJ, Maathuis MH, Muñoz J, Taurá P, Calatayud D, Leuvenink H, Rimola A, Ploeg RJ, García-Valdecasas JC. Superior preservation of DCD livers with continuous normothermic perfusion. *Ann Surg* 2011; **254**: 1000-1007 [PMID: 21862925 DOI: 10.1097/SLA.0b013e31822b8b2f]

117 **Schön MR**, Kollmar O, Wolf S, Schrem H, Matthes M, Akkoc N, Schnoy NC, Neuhaus P. Liver transplantation after organ preservation with normothermic extracorporeal perfusion. *Ann Surg* 2001; **233**: 114-123 [PMID: 11141233 DOI: 10.1097/00000658-200101000-00017]

118 **Vogel T**, Brockmann JG, Quaglia A, Morovat A, Jassem W, Heaton ND, Coussios CC, Friend PJ. The 24-hour normothermic machine perfusion of discarded human liver grafts. *Liver Transpl* 2017; **23**: 207-220 [PMID: 27809409 DOI: 10.1002/lt.24672]

119 **Ravikumar R**, Leuvenink H, Friend PJ. Normothermic liver preservation: a new paradigm? *Transpl Int* 2015; **28**: 690-699 [PMID: 25847684 DOI: 10.1111/tri.12576]

120 **Shigeta T**, Matsuno N, Obara H, Kanazawa H, Tanaka H, Fukuda A, Sakamoto S, Kasahara M, Mizunuma H, Enosawa S. Impact of rewarming preservation by continuous machine perfusion: improved post-transplant recovery in pigs. *Transplant Proc* 2013; **45**: 1684-1689 [PMID: 23769024 DOI: 10.1016/j.transproceed.2013.01.098]

121 **Banan B**, Xiao Z, Watson R, Xu M, Jia J, Upadhya GA, Mohanakumar T, Lin Y, Chapman W. Novel strategy to decrease reperfusion injuries and improve function of cold-preserved livers using normothermic ex vivo liver perfusion machine. *Liver Transpl* 2016; **22**: 333-343 [PMID: 26439190 DOI: 10.1002/lt.24352]

122 **Obara H**, Matsuno N, Shigeta T, Hirano T, Enosawa S, Mizunuma H. Temperature controlled machine perfusion system for liver. *Transplant Proc* 2013; **45**: 1690-1692 [PMID: 23769025 DOI: 10.1016/j.transproceed.2013.01.087]

123 **Bral M**, Gala-Lopez B, Bigam D, Kneteman N, Malcolm A, Livingstone S, Andres A, Emamaullee J, Russell L, Coussios C, West LJ, Friend PJ, Shapiro AM. Preliminary Single-Center Canadian Experience of Human Normothermic Ex Vivo Liver Perfusion: Results of a Clinical Trial. *Am J Transplant* 2017; **17**: 1071-1080 [PMID: 27639262 DOI: 10.1111/ajt.14049]

124 **Selzner M**, Goldaracena N, Echeverri J, Kaths JM, Linares I, Selzner N, Serrick C, Marquez M, Sapisochin G, Renner EL, Bhat M, McGilvray ID, Lilly L, Greig PD, Tsien C, Cattral MS, Ghanekar A, Grant DR. Normothermic ex vivo liver perfusion using steen solution as perfusate for human liver transplantation: First North American results. *Liver Transpl* 2016; **22**: 1501-1508 [PMID: 27339754 DOI: 10.1002/lt.24499]

125 **Liu Q,** Soliman B, Iuppa G, Nassar A, Hassan A, Diago Uso T, Hashimoto K, Aucejo F, Fujiki M, Eghtesad B, Cywinski J, Irefin S, Fung J, Abu-Elmagd K, Miller C, Quintini C. Abstract 276: First Report of Human Liver Transplantation After Normothermic Machine Perfusion (NMP) in the United States. *Am J Transplant* 2017; **17 Suppl 3**: Abstract 276

126 **Nasralla D**, Coussios CC, Mergental H, Akhtar MZ, Butler AJ, Ceresa CDL, Chiocchia V, Dutton SJ, García-Valdecasas JC, Heaton N, Imber C, Jassem W, Jochmans I, Karani J, Knight SR, Kocabayoglu P, Malagò M, Mirza D, Morris PJ, Pallan A, Paul A, Pavel M, Perera MTPR, Pirenne J, Ravikumar R, Russell L, Upponi S, Watson CJE, Weissenbacher A, Ploeg RJ, Friend PJ; Consortium for Organ Preservation in Europe. A randomized trial of normothermic preservation in liver transplantation. *Nature* 2018; **557**: 50-56 [PMID: 29670285 DOI: 10.1038/s41586-018-0047-9]

127 **Kim WR**, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, Harper AM, Wainright JL, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2015 Annual Data Report: Liver. *Am J Transplant* 2017; **17 Suppl 1**: 174-251 [PMID: 28052604 DOI: 10.1111/ajt.14126]

128 **Martins PN**. Normothermic machine preservation as an approach to decrease biliary complications of DCD liver grafts. *Am J Transplant* 2013; **13**: 3287-3288 [PMID: 24148669 DOI: 10.1111/ajt.12497]

129 **Brockmann J**, Reddy S, Coussios C, Pigott D, Guirriero D, Hughes D, Morovat A, Roy D, Winter L, Friend PJ. Normothermic perfusion: a new paradigm for organ preservation. *Ann Surg* 2009; **250**: 1-6 [PMID: 19561463 DOI: 10.1097/SLA.0b013e3181a63c10]

130 **Vairetti M**, Ferrigno A, Rizzo V, Richelmi P, Boncompagni E, Neri D, Freitas I, Cillo U. Subnormothermic machine perfusion protects against rat liver preservation injury: a comparative evaluation with conventional cold storage. *Transplant Proc* 2007; **39**: 1765-1767 [PMID: 17692606 DOI: 10.1016/j.transproceed.2007.06.002]

131 **Ferrigno A**, Rizzo V, Boncompagni E, Bianchi A, Gringeri E, Neri D, Richelmi P, Freitas I, Cillo U, Vairetti M. Machine perfusion at 20°C reduces preservation damage to livers from non-heart beating donors. *Cryobiology* 2011; **62**: 152-158 [PMID: 21315707 DOI: 10.1016/j.cryobiol.2011.02.004]

132 **Imber CJ**, St Peter SD, Lopez de Cenarruzabeitia I, Pigott D, James T, Taylor R, McGuire J, Hughes D, Butler A, Rees M, Friend PJ. Advantages of normothermic perfusion over cold storage in liver preservation. *Transplantation* 2002; **73**: 701-709 [PMID: 11907414 DOI: 10.1097/00007890-200203150-00008]

133 **Black SM**, Whitson BA, Velayutham M. EPR spectroscopy as a predictive tool for the assessment of marginal donor livers perfused on a normothermic ex vivo perfusion circuit. *Med Hypotheses* 2014; **82**: 627-630 [PMID: 24629357 DOI: 10.1016/j.mehy.2014.02.025]

134 **Banan B**, Watson R, Xu M, Lin Y, Chapman W. Development of a normothermic extracorporeal liver perfusion system toward improving viability and function of human extended criteria donor livers. *Liver Transpl* 2016; **22**: 979-993 [PMID: 27027254 DOI: 10.1002/lt.24451]

135 **Russo L**, Gracia-Sancho J, García-Calderó H, Marrone G, García-Pagán JC, García-Cardeña G, Bosch J. Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers. *Hepatology* 2012; **55**: 921-930 [PMID: 22031447 DOI: 10.1002/hep.24755]

136 **Pareja E**, Cortes M, Navarro R, Sanjuan F, López R, Mir J. Vascular complications after orthotopic liver transplantation: hepatic artery thrombosis. *Transplant Proc* 2010; **42**: 2970-2972 [PMID: 20970585 DOI: 10.1016/j.transproceed.2010.07.063]

137 **Varotti G**, Grazi GL, Vetrone G, Ercolani G, Cescon M, Del Gaudio M, Ravaioli M, Cavallari A, Pinna A. Causes of early acute graft failure after liver transplantation: analysis of a 17-year single-centre experience. *Clin Transplant* 2005; **19**: 492-500 [PMID: 16008594 DOI: 10.1111/j.1399-0012.2005.00373.x]

138 **Bernal W**, Hyyrylainen A, Gera A, Audimoolam VK, McPhail MJ, Auzinger G, Rela M, Heaton N, O'Grady JG, Wendon J, Williams R. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. *J Hepatol* 2013; **59**: 74-80 [PMID: 23439263 DOI: 10.1016/j.jhep.2013.02.010]

139 **Olthoff KM**, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, Shaked A, Christie JD. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. *Liver Transpl* 2010; **16**: 943-949 [PMID: 20677285 DOI: 10.1002/lt.22091]

140 **Jay CL**, Lyuksemburg V, Ladner DP, Wang E, Caicedo JC, Holl JL, Abecassis MM, Skaro AI. Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. *Ann Surg* 2011; **253**: 259-264 [PMID: 21245668 DOI: 10.1097/SLA.0b013e318204e658]

141 **op den Dries S**, Westerkamp AC, Karimian N, Gouw AS, Bruinsma BG, Markmann JF, Lisman T, Yeh H, Uygun K, Martins PN, Porte RJ. Injury to peribiliary glands and vascular plexus before liver transplantation predicts formation of non-anastomotic biliary strictures. *J Hepatol* 2014; **60**: 1172-1179 [PMID: 24560661 DOI: 10.1016/j.jhep.2014.02.010]

142 **Duffy JP**, Hong JC, Farmer DG, Ghobrial RM, Yersiz H, Hiatt JR, Busuttil RW. Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. *J Am Coll Surg* 2009; **208**: 896-903; discussion 903-5 [PMID: 19476857 DOI: 10.1016/j.jamcollsurg.2008.12.032]

143 **Briceño J**, Ciria R. Early graft dysfunction after liver transplantation. *Transplant Proc* 2010; **42**: 631-633 [PMID: 20304210 DOI: 10.1016/j.transproceed.2010.02.004]

144 **Nasralla D,** Consortium for Organ Preservation in Europe Liver Research Group, Ploeg R, Coussios C, Friend P. Abstract 560: Outcomes from a Multinational Randomised Controlled Trial Comparing Normothermic Machine Perfusion with Static Cold Storage in Human Liver Transplantation. *Am J Transplant* 2017; **17 Suppl 3**: Abstract 560

145 **Vogel T**, Brockmann JG, Pigott D, Neil DAH, Muthusamy ASR, Coussios CC, Friend PJ. Successful transplantation of porcine liver grafts following 48-hour normothermic preservation. *PLoS One* 2017; **12**: e0188494 [PMID: 29176869 DOI: 10.1371/journal.pone.0188494]

146 **Lee DD**, Croome KP, Shalev JA, Musto KR, Sharma M, Keaveny AP, Taner CB. Early allograft dysfunction after liver transplantation: an intermediate outcome measure for targeted improvements. *Ann Hepatol* 2016; **15**: 53-60 [PMID: 26626641 DOI: 10.5604/16652681.1184212]

147 **Angulo P**. Nonalcoholic fatty liver disease and liver transplantation. *Liver Transpl* 2006; **12**: 523-534 [PMID: 16555318 DOI: 10.1002/lt.20738]

148 **Hashimoto K**, Eghtesad B, Gunasekaran G, Fujiki M, Uso TD, Quintini C, Aucejo FN, Kelly DM, Winans CG, Vogt DP, Parker BM, Irefin SA, Miller CM, Fung JJ. Use of tissue plasminogen activator in liver transplantation from donation after cardiac death donors. *Am J Transplant* 2010; **10**: 2665-2672 [PMID: 21114643 DOI: 10.1111/j.1600-6143.2010.03337.x]

149 **Seal JB**, Bohorquez H, Reichman T, Kressel A, Ghanekar A, Cohen A, McGilvray ID, Cattral MS, Bruce D, Greig P, Carmody I, Grant D, Selzner M, Loss G. Thrombolytic protocol minimizes ischemic-type biliary complications in liver transplantation from donation after circulatory death donors. *Liver Transpl* 2015; **21**: 321-328 [PMID: 25545787 DOI: 10.1002/lt.24071]

150 **Nassar A,** Liu Q, Farias K, Tom C, D'Amico G, Bennett A, Abu-Elmagd K, Miller C, Fung J, Quintini C. Abstract B1141: Effect of Normothermic Machine Perfusion (NMP) Using Various Perfusates on the Hepatocellular and Biliary Epithelial Integrity in Porcine Donation after Cardiac Death (DCD) Models. Abstracts of the American Transplant Congress 2013. *Am J Transplant* 2013; **13 Suppl 5**: Abstract B1141

151 **Spitzer AL**, Lao OB, Dick AA, Bakthavatsalam R, Halldorson JB, Yeh MM, Upton MP, Reyes JD, Perkins JD. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. *Liver Transpl* 2010; **16**: 874-884 [PMID: 20583086 DOI: 10.1002/lt.22085]

152 **Angele MK**, Rentsch M, Hartl WH, Wittmann B, Graeb C, Jauch KW, Loehe F. Effect of graft steatosis on liver function and organ survival after liver transplantation. *Am J Surg* 2008; **195**: 214-220 [PMID: 18154767 DOI: 10.1016/j.amjsurg.2007.02.023]

153 **Westerkamp AC**, de Boer MT, van den Berg AP, Gouw AS, Porte RJ. Similar outcome after transplantation of moderate macrovesicular steatotic and nonsteatotic livers when the cold ischemia time is kept very short. *Transpl Int* 2015; **28**: 319-329 [PMID: 25545740 DOI: 10.1111/tri.12504]

154 **Nagrath D**, Xu H, Tanimura Y, Zuo R, Berthiaume F, Avila M, Yarmush R, Yarmush ML. Metabolic preconditioning of donor organs: defatting fatty livers by normothermic perfusion ex vivo. *Metab Eng* 2009; **11**: 274-283 [PMID: 19508897 DOI: 10.1016/j.ymben.2009.05.005]

155 **Boteon YL**, Wallace L, Boteon APCS, Mirza DF, Mergental H, Bhogal RH, Afford S. An effective protocol for pharmacological defatting of primary human hepatocytes which is non-toxic to cholangiocytes or intrahepatic endothelial cells. *PLoS One* 2018; **13**: e0201419 [PMID: 30044872 DOI: 10.1371/journal.pone.0201419]

156 **Scheuermann U**, Zhu M, Song M, Yerxa J, Gao Q, Davis RP, Zhang M, Parker W, Hartwig MG, Kwun J, Brennan TV, Lee J, Barbas AS. Damage-Associated Molecular Patterns Induce Inflammatory Injury During Machine Preservation of the Liver: Potential Targets to Enhance a Promising Technology. *Liver Transpl* 2019 [PMID: 30734488 DOI: 10.1002/lt.25429]

157 **Dondossola D**, Lonati C, Zanella A, Maggioni M, Antonelli B, Reggiani P, Gatti S, Rossi G. Preliminary Experience With Hypothermic Oxygenated Machine Perfusion in an Italian Liver Transplant Center. *Transplant Proc* 2019; **51**: 111-116 [PMID: 30736971 DOI: 10.1016/j.transproceed.2018.04.070]

**P-Reviewer:** Frena A **S-Editor:** Dou Y **L-Editor: E-Editor:**

**Specialty type:** Medicine, Research and Experimental

**Country of origin:** Russia

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Graft preservation solutions[31,32,58,59]**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **UW** | **HTK** | **CE** | **IGL-1** | **SCOT** |
| Potassium | High  | Low | Low  | High  | Low |
| HES | Yes | No | No | No | No |
| PEG | No | No | No | PEG-35 | PEG-20 |
| Impermeant substances  | Raffinose, lactobionate | No | Lactobionate | Raffinose, lactobionate | No |
| 3-yr graft survival | 75% | 69% (*P* < 0.0001) | 73% | 75% | N/A |
| Special features  | High viscosity, prevention of edema, ATP precursor and anti-oxidant components  | No oncotic agents, potent buffer system, lower viscosity and potentially better penetration to the liver microcirculation, reported risk for reduced graft survival | No oncotic agents, lower viscosity and potentially better penetration to the liver microcirculation | Reported to be advantageous for suboptimal livers | Reported to reduce transplant cholestasis, to be involved in “immune-camouflage” process[31, 58,59] |

UW: University of Wisconsin solution; HTK: Histidine-tryptophane-ketoglutarate solution; CE: Celsior solution; IGL-1: Institute Georges Lopez solution; SCOT: Tissue and Organ Conservation Solution; HES: Hydroxyethyl-starch; PEG: Polyethylene-glycol; ATP: Adenosine triphosphate.

**Table 2 Results of normothermic machine perfusion and static cold storage[92,104,123-126]**

|  |  |  |
| --- | --- | --- |
|  | **Normothermic machine perfusion** | **Static cold storage** |
| Max medium AST | 417-1252 U/L (range 84-15009 U/L) | 839-1474 U/L (range 153-8786 U/L) |
| Median INR | 1.05-1.1 (range 0.88-1.6) | 1.03-1.1 (range 0.90-2.2) |
| Median bilirubin | 25-79 μmol/L (range 8-344 μmol/L) | 30-48 μmol/L (range 9-340 μmol/L) |
| Median alkaline phosphatase | 139-245 U/L (range 40-626 U/L) | 147-243 U/L (range 58-743 U/L) |
| Early allograft dysfunction | ranged from 10% to 56% | ranged from 23% to 30% |
| Median ICU stay | 3-16 d (range 1-65 d) | 3-4 d (range 0-41 d) |
| Median hospital stay | 12-45 d (range 6-114 d) | 13-25 d (range 7-89 d) |
| Major complications | 10%-22% | 22%-37% |
| Graft survival | 80%-100% | 97.5%-100% |
| 30 d mortality | 2.5%-11% | 0-2.5% |

AST: Aspartate Aminotransferase; INR: International normalized ratio; ICU: Intensive care unit.